Jpmorgan Chase & CO Capricor Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 56,199 shares of CAPR stock, worth $1.06 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
56,199
Previous 10,818
419.5%
Holding current value
$1.06 Million
Previous $51,000
1574.51%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CAPR
# of Institutions
92Shares Held
8.13MCall Options Held
1.78MPut Options Held
1.4M-
Black Rock Inc. New York, NY1.63MShares$30.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.58MShares$29.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA638KShares$12 Million0.0% of portfolio
-
State Street Corp Boston, MA512KShares$9.64 Million0.0% of portfolio
-
Superstring Capital Management LP New York, NY337KShares$6.35 Million4.49% of portfolio
About CAPRICOR THERAPEUTICS, INC.
- Ticker CAPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,346,200
- Market Cap $458M
- Description
- Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...